RCZY-869

RCZY-869 is a highly potent, selective, and orally bioavailable covalent tri-complex inhibitor developed by Rongchang Pharmaceuticals. It specifically targets the GTP-bound (ON) state of the KRAS G12D mutation, which is a primary driver in various solid tumors including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). The drug's mechanism involves engaging cyclophilin A (CypA) to form a stable ternary complex with KRASG12D(ON), thereby blocking downstream effectors and suppressing MAPK signaling. In preclinical models, RCZY-869 has demonstrated superior antiproliferative activity and favorable pharmacokinetic properties compared to other ON-state inhibitors like RMC-9805, achieving robust tumor growth inhibition at lower exposures.